Premedication To Reduce Anxiety In Patients Undergoing Coronary Angiography And Percutaneous Coronary Intervention

Aims In this study, we examined the effects of the routinely administration of benzodiazepines on reducing periprocedural anxiety versus no premedication.Methods In this open label study, we enrolled 1683 patients undergoing diagnostic coronary angiograrns (CAG) or percutaneous coronary interventions (PCI). Randomisation was simulated by systematically allocating patients in monthly rotational periods to lorazepam 1 mg/sl, oxazepam 10 mg/po, diazepam 5 mg/po, midazolam 7.5 mg/po or no premedication. Anxiety was measured at four different time points using the one-item Visual Analogue Scale for Anxiety (VAS score) ranging from 0 to 10. The primary outcome was the difference in anxiety reduction (Delta VAS, preprocedure to postprocedure), between the different premedication strategies versus no premedication.Results Anxiety reduction was larger in patients premedicated with lorazepam (Delta VAS=-2.0, SE=1.6, P=0.007) or diazepam (Delta VAS=-2.0, SE=1.5, p=0.003) compared with patients without any premedication (Delta VAS=-1.4, SE=1.2). The use of midazolam or oxazepam did not lead to a significant reduction in anxiety compared with patients who did not receive premedication. Additionally, a high number of patients treated with midazolam (N=39, 19.8%) developed side effects.Conclusions In this study, the use of lorazepam or diazepam was associated with a significant, but modest anxiety reduction in patients undergoing CAG or PCI. This study does not support the standard use of oxazepam or midazolam as premedication to reduce anxiety.